Description
Anti-IL1A antibody takes advantage of the enrichment of some small molecules such as ATP in the tumor microenvironment, and activates the antibody by using the small molecule as a medium, so that the antibody is specifically activated only in the tumor.
Applications
"On-target" tumor antigen binding
Technology
ATP-mediated antibody engineering technology
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IL1A antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
interleukin 1, alpha
Background
IL1A; interleukin 1; alpha; IL1; IL-1A; IL1F1; IL1-ALPHA; interleukin-1 alpha; IL-1 alpha; hematopoietin-1; preinterleukin 1 alpha; pro-interleukin-1-alpha; MABp1; Xilonix™; CA-18C3; CV-18C3; RA-18C3; T2-18C3
Antibody Clone
AES-0622-ZP696
Description
Anti-IL1A antibody takes advantage of the enrichment of some small molecules such as ATP in the tumor microenvironment, and activates the antibody by using the small molecule as a medium, so that the antibody is specifically activated only in the tumor.
